期刊
ANTICANCER RESEARCH
卷 39, 期 11, 页码 6073-6086出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.13815
关键词
Adenovirus; cancer stem cells; DNA internalization; TAMRA; U87 cell line
类别
资金
- State Project of the Institute of Cytology and Genetics [0324-2019-0042]
- Novosibirsk State University [6.5546.2017]
- Russian Foundation for Basic Research [18-34-20016]
- Novosibirsk State University
Background/Aim: Oncolytic adenoviruses are promising therapeutic agents against both the bulk of tumor cells and cancer stem cells. The present study intended to test the oncolytic capability of adenovirus serotype 6 (Ad6), which has a lower seroprevalence and hepatotoxicity relatively to adenovirus 5 (Ad5), against the glioblastoma and its cancer stem cells. Materials and Methods: Oncolytic efficacy of Ad6 was compared to widespread Ad5 both in vitro and in vivo, using the U87 and U251 human glioblastoma cell lines and subcutaneously transplanted U87 cells in SCID mice, respectively. Results: Ad6 had a dose-dependent cytotoxicity toward glioblastoma cells in vitro and its intratumoral injections lead to a significant (p< 0.05) decrease in volume of U87 xenografts, similarly to Ad5. Based on the innate capability of glioblastoma cancer stem cells to internalize a fluorescent-labeled double-stranded DNA probe, the spatial localization of these cells was estimated and it was shown that the number of cancer stem cells tended to decrease under adenovirus therapy as compared to the control group. Conclusion: Ad6 was shown to be a promising agent for treating glioblastomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据